Influence of hydroxychloroquine on the bioavailability of oral metoprolol

被引:80
作者
Somer, M [1 ]
Kallio, J [1 ]
Pesonen, U [1 ]
Pyykkö, K [1 ]
Huupponen, R [1 ]
Scheinin, M [1 ]
机构
[1] Univ Turku, Dept Pharmacol & Clin Pharmacol, FIN-20520 Turku, Finland
关键词
CYP2D6; interaction; hydroxychloroquine (HCQ); metoprolol; dextromethorphan (DM);
D O I
10.1046/j.1365-2125.2000.00197.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Hydroxychloroquine (HCQ) is used widely in the treatment of chronic inflammatory diseases such as rheumatoid arthritis. Since there is great interindividual variability in the pharmacokinetics of HCQ and chloroquine is a potent inhibitor of CYP2D6-catalysed pathways in vitro, we wished to study the interaction of HCQ with CYP2D6-mediated metabolism of other drugs in vivo. Methods Metoprolol and dextromethorphan (DM) were selected as probe drugs because they are well-studied and widely used test substrates of CYP2D6. In this randomized, double-blind crossover study, seven healthy volunteers with extensive metabolizer phenotype for CYP2D6 ingested either 400 mg hydroxychloroquine or placebo daily for 8 days after which single oral dose pharmacokinetics of metoprolol were investigated. Dextromethorphan metabolic ratio (DM-MR) was also determined at baseline and after the ingestion of HCQ or placebo. Results Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 +/- 4.6%) and maximal plasma concentrations (72 +/- 6.9%) of metoprolol. While the DM-MR values were not significantly changed, the phenotypic classification of one individual, who was heterozygous for a mutant CYP2D6 allele, was converted to a poor metabolizer by HCQ administration. Conclusions HCQ inhibits metoprolol metabolism most probably by inhibiting its biotransformation by CYP2D6. The inhibitory effect of HCQ on dextromethorphan metabolism was not apparent when DM-MR was used as an indicator, except in an individual with limited CYP2D6 capacity.
引用
收藏
页码:549 / 554
页数:6
相关论文
共 36 条
  • [1] Abdel-Rahman SM, 1999, DRUG METAB DISPOS, V27, P770
  • [2] Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail
    Adedoyin, A
    Frye, RF
    Mauro, K
    Branch, RA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (03) : 215 - 219
  • [3] GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19
    BERTILSSON, L
    [J]. CLINICAL PHARMACOKINETICS, 1995, 29 (03) : 192 - 209
  • [4] BORG KO, 1975, ACTA PHARMACOL TOX, V36, P125
  • [5] HEMATOLOGIC DISPOSITION OF HYDROXYCHLOROQUINE ENANTIOMERS
    BROCKS, DR
    SKEITH, KJ
    JOHNSTON, C
    EMAMIBAFRANI, J
    DAVIS, P
    RUSSELL, AS
    JAMALI, F
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (11) : 1088 - 1097
  • [6] DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION
    BROLY, F
    GAEDIGK, A
    HEIM, M
    EICHELBAUM, M
    MORIKE, K
    MEYER, UA
    [J]. DNA AND CELL BIOLOGY, 1991, 10 (08) : 545 - 558
  • [7] The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans
    Capon, DA
    Bochner, F
    Kerry, N
    Mikus, G
    Danz, C
    Somogyi, AA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (03) : 295 - 307
  • [8] Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects
    Chládek, J
    Zimová, G
    Martínková, J
    Tuma, I
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1999, 13 (04) : 508 - 515
  • [9] DEXTROMETHORPHAN AND CAFFEINE AS PROBES FOR SIMULTANEOUS DETERMINATION OF DEBRISOQUIN-OXIDATION AND N-ACETYLATION PHENOTYPES IN CHILDREN
    EVANS, WE
    RELLING, MV
    PETROS, WP
    MEYER, WH
    MIRRO, J
    CROM, WR
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (05) : 568 - 573
  • [10] Inhibition of dextromethorphan metabolism by moclobemide
    Härtter, S
    Dingemanse, J
    Baier, D
    Ziegler, G
    Hiemke, C
    [J]. PSYCHOPHARMACOLOGY, 1998, 135 (01) : 22 - 26